Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine

Journal of General Virology

Volumn 84, Issue 2, 2003, Pages 287-291

  Phumiamorn, Supaporn ^a   Sato, Hitoshi ^a   Kamiyama, Tomoko ^a   Kurokawa, Masahiko ^a   Shiraki, Kimiyasu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; CHICKENPOX VACCINE; HEPATITIS B SURFACE ANTIGEN; INACTIVATED VACCINE; LIVE VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; CELLULAR IMMUNITY; CHICKENPOX; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG ACTIVITY; HELPER CELL; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; INOCULATION; MALE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VARICELLA ZOSTER VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHICKENPOX VACCINE; GUINEA PIGS; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNIZATION; TH1 CELLS;

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 3;

EID: 0037309097     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.18692-0     Document Type: Review

References (30)

1. Abbas, A. K., Murphy, K. M. & Sher, A. (1996). Functional diversity of helper T lymphocytes. Nature 383, 787-793.
2. Arvin, A. M. & Gershon, A. A. (1996). Live attenuated varicella vaccine. Annu Rev Microbiol 50, 59-100.
3. Asano, Y., Shiraki, K., Takahashi, M., Nagai, H., Ozaki, T. & Yazaki, T. (1981). Soluble skin test antigen of varicella-zoster virus prepared from the fluid of infected cultures. J Infect Dis 143, 684-692.
4. Asano, Y., Itakura, N., Hiroishi, Y. & 7 other authors (1985). Viral replication and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine recipients. J Infect Dis 152, 863-868.
5. Baba, K., Tsuda, N., Yabuuchi, H., Konishi, S., Fujinami, A., Tsujino, G. & Takahashi, M. (1980). Prevention of varicella in urgent cases by passive transfer of vaccine-induced immunity. Biken J 23, 89-94.
6. Berger, R., Luescher, D. & Just, M. (1984). Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis 149, 647-649.
7. Berger, R., Trannoy, E., Hollander, G., Bailleux, F., Rudin, C. & Creusvaux, H. (1998). A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. J Infect Dis 178 (Suppl. 1), S99-S103.
8. Diaz, P. S., Smith, S., Hunter, E. & Arvin, A. M. (1989). T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Infect Dis 142, 636-641.
9. Finkelman, F. D. (1995). Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease. J Exp Med 182, 279-282.
10. Heineman, T. C., Connelly, B. L., Bourne, N., Stanberry, L. R. & Cohen, J. (1995). Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 69, 8109-8113.
11. Jack, A. D., Hall, A. J., Maine, N., Mendy, M. & Whittle, H. C. (1999). What level of hepatitis B antibody is protective? J Infect Dis 179, 489-492.
12. Jenkins, D. E., Redman, R. L., Lam, E. M., Liu, C., Lin, I. & Arvin, A. M. (1998). Interleukin (IL)-10, IL-12, and interferon-γ production in primary and memory immune responses to varicella-zoster virus. J Infect Dis 178, 940-948.
13. Kamiya, H., Ihara, T., Hattori, A., Iwasa, T., Sakurai, M., Izawa, T., Yamada, A. & Takahashi, M. (1977). Diagnostic skin reactions with varicella virus antigen and clinical application of the test. J Infect Dis 136, 784-788.
14. Kamiyama, T., Sato, H., Takahara, T., Kageyama, S. & Shiraki, K. (2000). Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen. J Infect Dis 181, 1158-1161.
15. LaRussa, P., Steinberg, S. P., Seeman, M. D. & Gershon, A. A. (1985). Determination of immunity to varicella-zoster virus by means of an intradermal skin test. J Infect Dis 152, 869-875.
16. Lau, D. T., Khokhar, M. F. Doo, E. & 10 other authors (2000). Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32, 828-834.
17. Levin, M. J., Murray, M., Zerbe, G. O., White, C. J. & Hayward, A. R. (1994). Immune response of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 170, 522-526.
18. Levin, M. J., Barber, D., Goldblatt, E., Jones, M., LaFleur, B., Chan, C., Stinson, D., Zerbe, G. O. & Hayward, A. R. (1998). Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 178 (Suppl. 1), S109-S112.
19. Moser, M. & Murphy, K. M. (2000). Dendritic cell regulation of Th1-Th2 development. Nat Immunol 1, 199-205.
20. Rossol, S., Marinos, G., Carucci, P., Singer, M. V., Williams, R. & Naoumov, N. V. (1997). Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 99, 3025-3033.
21. Sato, H., Kageyama, S., Imakita, M., Ida, M., Yamamura, J., Kurokawa, M. & Shiraki, K. (1998). Immune response to varicella-zoster virus glycoproteins in guinea pigs infected with Oka varicella vaccine. Vaccine 16, 1263-1269.
22. Shiraki, K., Yamanishi, K. & Takahashi, M. (1984). Biologic and immunologic characterization of the soluble skin-test antigen of varicella-zoster virus. J Infect Dis 149, 501-504.
23. Shiraki, K., Hayakawa, Y., Mori, H., Namazue, J., Takamizawa, A., Yoshida, I., Yamanishi, K. & Takahashi, M. (1991). Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen. J Gen Virol 72, 1393-1399.
24. Shiraki, K., Sato, H., Yamamura, J., Li, Z. H., Yokoyama, T., Hasegawa, T., Okuno, T., Kurokawa, M. & Kageyama, S. (1997). Functions of purified gB, gE:gI, and gH:gL, and their sialyl residues in varicella-zoster virus infection. Arch Virol 142, 2295-2301.
25. Shiraki, K., Sato, H., Yoshida, Y., Yamamura, J., Tsurita, M., Kurokawa, M. & Kageyama, S. (2001). Construftion of Oka varicella vaccine expressing human immunodeficiency virus Env antigen. J Med Virol 64, 89-95.
26. Singh, M. & O'Hagan, D. (1999). Advance in vaccine adjuvants. Nat Biotechnol 17, 1075-1081.
27. Takahashi, M., Otsuka, T., Okuno, Y., Asano, Y. & Yazaki, T. (1974). Live vaccine used to prevent the spread of varicella in children in hospital. Lancet ii, 1288-1290.
28. Takahashi, M., Iketani, T., Sasada, K., Hara, J., Kamiya, H., Asano, Y., Baba, K. & Shiraki, K. (1998). Immunization of the elderly and patients with collagen vascular diseases with live varicella vaccine and use of varicella skin antigen. J Infect Dis 166 (Suppl. 1), S58-S62.
29. Takahashi, M., Kamiya, H., Asano, Y., Shiraki, K., Baba, K., Otsuka, T., Hirota, T. & Yamanishi, K. (2001). Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction. Arch Virol 17, 161-172.
30. Vazquez, M., LaRussa, P. S., Gershon, A. A., Steinberg, S. P., Freudigman, K. & Shapiro, E. D. (2001). The effectiveness of the varicella vaccine in clinical practice. New Engl J Med 344, 955-960.